(Q54454976)

30 May 2018

meta-analysis

0 references

title

A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. (English)

1 reference

30 May 2018

0 references

1 reference

5

1 reference

30 May 2018

author name string

K Jordan

1

1 reference

30 May 2018

A Hinke

2

1 reference

30 May 2018

A Grothey

3

1 reference

30 May 2018

W Voigt

4

1 reference

30 May 2018

H-H Wolf

6

1 reference

30 May 2018

H-J Schmoll

7

1 reference

30 May 2018

publication date

5 January 2007

1 reference

30 May 2018

Supportive Care in Cancer

published in

1 reference

30 May 2018

volume

15

1 reference

30 May 2018

issue

9

1 reference

30 May 2018

page(s)

1023-1033

1 reference

30 May 2018

https://scigraph.springernature.com/pub.10.1007/s00520-006-0186-7

exact match

0 references

cites work

Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00520-006-0186-7

Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetr

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00520-006-0186-7

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

21 January 2018

1 reference

12 December 2020

Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy

1 reference

12 December 2020

[Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research]

1 reference

12 December 2020

Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study

1 reference

12 December 2020

A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group

1 reference

12 December 2020

A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy.

1 reference

12 December 2020

Quality of life studies in chemotherapy-induced emesis.

1 reference

12 December 2020

Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting

1 reference

12 December 2020

A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group

1 reference

12 December 2020

Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Ca

1 reference

12 December 2020

Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy

1 reference

12 December 2020

5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—A randomised study

1 reference

12 December 2020

Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials

1 reference

12 December 2020

Intravenous granisetron--establishing the optimal dose. The Granisetron Study Group

1 reference

12 December 2020

Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation

1 reference

12 December 2020

Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions

1 reference

12 December 2020

Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy

1 reference

12 December 2020

Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy: a randomized study

1 reference

12 December 2020

[A randomized trial of tropisetron in the prophylaxis of nausea and vomiting induced by chemotherapy]

1 reference

12 December 2020

Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial

1 reference

12 December 2020

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.

1 reference

12 December 2020

Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study

1 reference

12 December 2020

Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy

1 reference

12 December 2020

Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide

1 reference

12 December 2020

Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.

1 reference

12 December 2020

Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group

1 reference

12 December 2020

Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesis

1 reference

12 December 2020

An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens.

1 reference

12 December 2020

Radiation-induced emesis: a prospective observational multicenter Italian trial. The Italian Group for Antiemetic Research in Radiotherapy

1 reference

12 December 2020

Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group

1 reference

12 December 2020

Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Em

1 reference

12 December 2020

Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin

1 reference

12 December 2020

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

1 reference

12 December 2020

Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin

1 reference

12 December 2020

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

1 reference

12 December 2020

Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes

1 reference

12 December 2020

Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.

1 reference

12 December 2020

Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy

1 reference

12 December 2020

A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group

1 reference

12 December 2020

Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.

1 reference

12 December 2020

Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy.

1 reference

12 December 2020

Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting

1 reference

12 December 2020

A Comparison of Oral Ondansetron and Intravenous Granisetron for the Prevention of Nausea and Emesis Associated with Cisplatin-Based Chemotherapy

1 reference

12 December 2020

Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research

1 reference

12 December 2020

Comparison of two different doses of ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced emesis.

1 reference

12 December 2020

Ondansetron and Tropisetron with Dexamethasone in the Prophylaxis of Acute Vomiting Induced by Non-cisplatin-Containing Chemotherapy

1 reference

12 December 2020

Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy

1 reference

12 December 2020

A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.

1 reference

12 December 2020

A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. Ondansetron Acute Emesis Study Group

1 reference

12 December 2020

Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study

1 reference

12 December 2020

BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors.

1 reference

12 December 2020

[Granisetron (per os) compared with ondansetron (per os) in the prevention of nausea and vomiting induced by mildly emetogenic chemotherapies. Groupe de Recherches en Cancerologie du Nord]

1 reference

12 December 2020

Beta blockade during and after myocardial infarction: an overview of the randomized trials

1 reference

12 December 2020

Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron. A cost-benefit analysis

1 reference

12 December 2020

Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis

1 reference

12 December 2020

Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study

1 reference

12 December 2020

Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study

1 reference

12 December 2020

[Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron]

1 reference

12 December 2020

10.1007/S00520-006-0186-7

Identifiers

DOI

1 reference

30 May 2018

1 reference

30 May 2018